Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256542 · ClinicalTrials.gov registry record · Phase 2
Study of U101 for Bladder Pain and/or Urgency
A Phase 2 study of Interstitial Cystitis and Pelvic Pain, sponsored by Urigen.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT00256542 is a Phase 2 study of Interstitial Cystitis and Pelvic Pain that has completed, run by Urigen. The registered enrollment target is 90 participants, below the 359-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (75% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00256542, a Phase 2 study of Interstitial Cystitis and Pelvic Pain, has completed, sponsored by Urigen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.
Conditions Studied
Interventions
- DRUG Alkalinized Lidocaine-Heparin
Study Locations (9)
California
- UCSD Medical Center - San Diego
Georgia
- Georgia Urology - Cartersville
Illinois
- St. Mary's Good Samaritan - Centralia
Kansas
- The Urogynecology Center - Overland Park
Michigan
- Mid-Michigan Health Centers - Jackson
New York
- Central Park Urology - New York
North Carolina
- The Urology Center - Greensboro
Oklahoma
- Urologic Specialists of Oklahoma, Inc. - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00256542
The ClinicalTrials.gov registry entry for NCT00256542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 359-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (75% lower). The listed sponsor is Urigen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 1 intervention - of which Alkalinized Lidocaine-Heparin is the first listed.
NCT00256542 reports 9 study locations spanning 9 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT00256542 about?
NCT00256542 is a clinical study titled "Study of U101 for Bladder Pain and/or Urgency". The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.
What is the current status of trial NCT00256542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2006-01. Estimated completion is 2006-09.
What conditions does trial NCT00256542 study?
This clinical trial studies the following conditions: Interstitial Cystitis, Pelvic Pain, Bladder Diseases.
What interventions are being tested in trial NCT00256542?
The interventions under investigation include: Alkalinized Lidocaine-Heparin (DRUG).
Who is sponsoring clinical trial NCT00256542?
This trial is sponsored by Urigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00256542 being conducted?
This trial has 9 study locations across California, Georgia, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Cystitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
RECRUITING · Phase 2
-
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
RECRUITING · Phase 2
-
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
RECRUITING · Phase 2
-
Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC
COMPLETED · Phase 2
-
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
RECRUITING · NA
-
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.